ResMed Inc.

NYSE:RMD Lagerbericht

Marktkapitalisierung: US$30.2b

ResMed Management

Management Kriterienprüfungen 4/4

ResMed's CEO ist Mick Farrell , ernannt in Mar 2013, hat eine Amtszeit von 11.25 Jahren. Die jährliche Gesamtvergütung beträgt $13.87M , bestehend aus 8.1% Gehalt und 91.9% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.3% der Aktien des Unternehmens, im Wert von $93.58M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 3.3 Jahre bzw. 8.6 Jahre.

Wichtige Informationen

Mick Farrell

Geschäftsführender

US$13.9m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts8.1%
Amtszeit als Geschäftsführer11.3yrs
Eigentum des Geschäftsführers0.3%
Durchschnittliche Amtszeit des Managements3.3yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder8.6yrs

Jüngste Management Updates

Shareholders May Find It Hard To Justify Increasing ResMed Inc.'s (NYSE:RMD) CEO Compensation For Now

Nov 10
Shareholders May Find It Hard To Justify Increasing ResMed Inc.'s (NYSE:RMD) CEO Compensation For Now

Recent updates

ResMed (NYSE:RMD) Seems To Use Debt Quite Sensibly

Apr 30
ResMed (NYSE:RMD) Seems To Use Debt Quite Sensibly

Earnings Beat: ResMed Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Apr 30
Earnings Beat: ResMed Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

ResMed Inc.'s (NYSE:RMD) Popularity With Investors Is Clear

Apr 18
ResMed Inc.'s (NYSE:RMD) Popularity With Investors Is Clear

With EPS Growth And More, ResMed (NYSE:RMD) Makes An Interesting Case

Mar 22
With EPS Growth And More, ResMed (NYSE:RMD) Makes An Interesting Case

Capital Investments At ResMed (NYSE:RMD) Point To A Promising Future

Mar 10
Capital Investments At ResMed (NYSE:RMD) Point To A Promising Future

An Intrinsic Calculation For ResMed Inc. (NYSE:RMD) Suggests It's 30% Undervalued

Feb 12
An Intrinsic Calculation For ResMed Inc. (NYSE:RMD) Suggests It's 30% Undervalued

Why ResMed Is One Of My Top Picks In 2024

Jan 22

A First Look At ResMed

Jan 09

ResMed Inc.'s (NYSE:RMD) Share Price Could Signal Some Risk

Dec 20
ResMed Inc.'s (NYSE:RMD) Share Price Could Signal Some Risk

Why You Should Care About ResMed's (NYSE:RMD) Strong Returns On Capital

Dec 06
Why You Should Care About ResMed's (NYSE:RMD) Strong Returns On Capital

Shareholders May Find It Hard To Justify Increasing ResMed Inc.'s (NYSE:RMD) CEO Compensation For Now

Nov 10
Shareholders May Find It Hard To Justify Increasing ResMed Inc.'s (NYSE:RMD) CEO Compensation For Now

Are Investors Undervaluing ResMed Inc. (NYSE:RMD) By 41%?

Nov 01
Are Investors Undervaluing ResMed Inc. (NYSE:RMD) By 41%?

ResMed: Weight-Loss Drug Worries Provide Buying Opportunity

Oct 28

ResMed: Stock Re-Rating To 20x Forward P/E Is A Buy Opportunity

Sep 12

ResMed Has Become A Steal (Rating Upgrade)

Aug 10

ResMed's (NYSE:RMD) Shareholders Will Receive A Bigger Dividend Than Last Year

Aug 07
ResMed's (NYSE:RMD) Shareholders Will Receive A Bigger Dividend Than Last Year

ResMed (NYSE:RMD) Has Some Way To Go To Become A Multi-Bagger

Jul 30
ResMed (NYSE:RMD) Has Some Way To Go To Become A Multi-Bagger

Here's Why We Think ResMed (NYSE:RMD) Might Deserve Your Attention Today

Jul 16
Here's Why We Think ResMed (NYSE:RMD) Might Deserve Your Attention Today

Compound Your Wealth With ResMed

Jul 04

A Look At The Fair Value Of ResMed Inc. (NYSE:RMD)

Jul 02
A Look At The Fair Value Of ResMed Inc. (NYSE:RMD)

We Think ResMed (NYSE:RMD) Can Stay On Top Of Its Debt

May 26
We Think ResMed (NYSE:RMD) Can Stay On Top Of Its Debt

ResMed (NYSE:RMD) Could Be Struggling To Allocate Capital

Apr 24
ResMed (NYSE:RMD) Could Be Struggling To Allocate Capital

Here's Why ResMed (NYSE:RMD) Has Caught The Eye Of Investors

Apr 09
Here's Why ResMed (NYSE:RMD) Has Caught The Eye Of Investors

A Look At The Intrinsic Value Of ResMed Inc. (NYSE:RMD)

Mar 26
A Look At The Intrinsic Value Of ResMed Inc. (NYSE:RMD)

ResMed goes ex dividend tomorrow

Feb 07

ResMed (NYSE:RMD) Seems To Use Debt Quite Sensibly

Feb 06
ResMed (NYSE:RMD) Seems To Use Debt Quite Sensibly

ResMed: The GARP Story Continues, Technicals Showing Vital Signs

Jan 26

Why The 23% Return On Capital At ResMed (NYSE:RMD) Should Have Your Attention

Jan 23
Why The 23% Return On Capital At ResMed (NYSE:RMD) Should Have Your Attention

We Ran A Stock Scan For Earnings Growth And ResMed (NYSE:RMD) Passed With Ease

Dec 28
We Ran A Stock Scan For Earnings Growth And ResMed (NYSE:RMD) Passed With Ease

Calculating The Fair Value Of ResMed Inc. (NYSE:RMD)

Dec 16
Calculating The Fair Value Of ResMed Inc. (NYSE:RMD)

ResMed: Strong Earnings Growth Supports The High Valuation, Unclear Technical Trends

Nov 14

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Mick Farrell im Vergleich zu den Einnahmen von ResMed verändert?
DatumGesamtvergütungGehaltUnternehmensgewinne
Mar 31 2024n/an/a

US$958m

Dec 31 2023n/an/a

US$890m

Sep 30 2023n/an/a

US$907m

Jun 30 2023US$14mUS$1m

US$898m

Mar 31 2023n/an/a

US$863m

Dec 31 2022n/an/a

US$809m

Sep 30 2022n/an/a

US$786m

Jun 30 2022US$12mUS$1m

US$779m

Mar 31 2022n/an/a

US$779m

Dec 31 2021n/an/a

US$522m

Sep 30 2021n/an/a

US$500m

Jun 30 2021US$10mUS$1m

US$475m

Mar 31 2021n/an/a

US$457m

Dec 31 2020n/an/a

US$699m

Sep 30 2020n/an/a

US$680m

Jun 30 2020US$10mUS$1m

US$622m

Mar 31 2020n/an/a

US$513m

Dec 31 2019n/an/a

US$455m

Sep 30 2019n/an/a

US$419m

Jun 30 2019US$10mUS$967k

US$405m

Mar 31 2019n/an/a

US$446m

Dec 31 2018n/an/a

US$450m

Sep 30 2018n/an/a

US$335m

Jun 30 2018US$9mUS$934k

US$316m

Mar 31 2018n/an/a

US$307m

Dec 31 2017n/an/a

US$285m

Sep 30 2017n/an/a

US$352m

Jun 30 2017US$8mUS$890k

US$342m

Vergütung im Vergleich zum Markt: MickDie Gesamtvergütung ($USD13.87M) liegt im Durchschnitt der Unternehmen ähnlicher Größe auf dem Markt US ($USD13.53M).

Entschädigung vs. Einkommen: MickDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

Mick Farrell (52 yo)

11.3yrs

Amtszeit

US$13,868,641

Vergütung

Mr. Michael J. Farrell, also known as Mick, BE, SM, MBA, served as Director of Fullbay, Inc. since May 2023 until 2023. He serves as Member of Advisory Board at Green Sun Medical, LLC. He serves as the Chi...

Führungsteam

NamePositionAmtszeitVergütungEigentümerschaft
Michael Farrell
CEO & Chairman11.3yrsUS$13.87m0.30%
$ 91.6m
Peter Farrell
Founderno dataUS$680.27k0.060%
$ 18.0m
Brett Sandercock
Chief Financial Officer18.4yrsUS$3.11m0.062%
$ 18.7m
Robert Douglas
Special Advisorless than a yearUS$6.67m0.18%
$ 54.4m
Kaushik Ghoshal
Chief Commercial Officer - SaaS2.3yrsUS$3.31m0.0088%
$ 2.7m
Amy Wakeham
Chief Investor Relations Officer1.2yrskeine Datenkeine Daten
Michael Rider
Chief Legal Officerless than a yearkeine Daten0.0044%
$ 1.3m
Jim Ellis
Chief Compliance Officer6.4yrskeine Datenkeine Daten
Yvonne-Katrin Pucknat
Chief Marketing Officerless than a yearkeine Datenkeine Daten
Vered Keisar
Chief People Officer3.3yrskeine Datenkeine Daten
Hemanth Reddy
Chief Strategy Officer9.5yrskeine Datenkeine Daten
Justin Leong
Chief Product Officer8.1yrskeine Daten0.045%
$ 13.7m

3.3yrs

Durchschnittliche Betriebszugehörigkeit

57yo

Durchschnittliches Alter

Erfahrenes Management: RMDDas Führungsteam des Unternehmens gilt als erfahren (3.3 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

NamePositionAmtszeitVergütungEigentümerschaft
Michael Farrell
CEO & Chairman11.3yrsUS$13.87m0.30%
$ 91.6m
Peter Farrell
Founder35yrsUS$680.27k0.060%
$ 18.0m
Richard Sulpizio
Independent Director18.8yrsUS$340.06k0.010%
$ 3.1m
Ronald Taylor
Lead Independent Director19.4yrsUS$372.56k0.014%
$ 4.3m
Jan De Witte
Independent Non-Executive Director5.1yrsUS$320.06k0.0039%
$ 1.2m
Harjit Gill
Independent Director5.6yrsUS$320.06k0.0049%
$ 1.5m
Carol Burt
Independent Director10.6yrsUS$360.06k0.010%
$ 3.1m
Karen Drexler
Independent Director6.6yrsUS$320.06k0.0052%
$ 1.6m
Desney Tan
Independent Director2.6yrsUS$320.06k0.0014%
$ 426.3k
John Hernandez
Independent Director2.6yrsUS$320.06k0.0014%
$ 426.3k

8.6yrs

Durchschnittliche Betriebszugehörigkeit

62yo

Durchschnittliches Alter

Erfahrener Vorstand: RMDDie Vorstandsmitglieder gelten als erfahren (8.6 Jahre durchschnittliche Amtszeit).